Naveed Saleh, MD, MS

In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.

Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.

In elderly patients with brain metastasis secondary to small cell lung cancer, whole brain radiation therapy was linked to a modest rise in survival. 

Researchers evaluated the response of patients with BCC to fractionated photodynamic therapy at 30 days after treatment.